-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the continuous expansion of the pharmaceutical market and the accelerating development of pharmaceutical technology, the entire pharmaceutical equipment industry has also begun to develop continuously
.
In this context, a large number of companies have ushered in the growth of performance, especially the leading companies
.
In order to maintain performance growth, pharmaceutical machine companies will continue to increase investment in research and development (Photo source: Pharmaceutical Network) At present, the listed companies in the domestic pharmaceutical equipment industry mainly include Xinhua Medical, Tofflon, Chutian Technology, Huasheng Co.
, Ltd.
, Tailin Biotechnology , Canaan Technology,
etc.
On the whole, the performance report cards of most listed pharmaceutical machine companies in 2021 are very dazzling.
Among them, the leading companies represented by Chutian and Tofflon have outstanding performance, and their net profit has increased significantly
.
For example, Chutian Technology disclosed in last year's third quarterly report that the company's main income was 3.
682 billion yuan, a year-on-year increase of 67.
24%; the net profit attributable to the parent was 401 million yuan, a year-on-year increase of 723.
53%
.
It also said that the main reason for the increase in revenue was a 98% increase in new orders compared to the same period in 2020
.
In addition, the third quarter report released by Xinhua Medical on October 28 also showed that the revenue in the first three quarters of 2021 was 7.
355 billion yuan, a year-on-year increase of 12.
60%, and the net profit was 438 million yuan, a year-on-year increase of 105.
59%
.
In addition, Tofflon expects that the net profit in the first three quarters of 2021 will also reach 519 million-562 million yuan, an increase of 80%-95% year-on-year; the net profit attributable to shareholders of listed companies is 558 million yuan, an increase of 93.
69% over the same period last year.
%
.
In addition to the continuous growth in performance, it is worth noting that the R&D investment of major enterprises is actually increasing continuously
.
Among them, Chutian Technology is very prominent in R&D investment.
Its R&D investment accounts for a high ratio of about 10% of revenue every year.
In the first three quarters of 2021, the company's R&D investment reached more than 300 million, a year-on-year increase of more than 60%
.
Since 2013, Tofflon's R&D investment has basically maintained at about 7% of its operating income, and its investment has continued to increase.
.
It is reported that in the first three quarters of this year, Tofflon's R&D expenses have exceeded the R&D expenses of 156 million yuan in 2020, an increase of 74.
81% over the same period of the previous year, reaching 166 million yuan
.
It can be seen from the above that R&D investment has become one of the core competitiveness of pharmaceutical machine companies to be invincible in the pharmaceutical equipment market
.
At the same time, innovation has also become an inexhaustible driving force for the development of pharmaceutical machine companies
.
Affected by this, the industry predicts that in the future, pharmaceutical machine companies will only continue to develop new technologies and products according to the needs of the industry and customers, innovate, improve and upgrade existing equipment, improve the level of China's pharmaceutical machine manufacturing industry, narrow the gap with imported equipment, and have More room for development
.
Of course, in the context of increasing innovation efforts, the industry believes that the import substitution of domestic pharmaceutical machines is also expected to accelerate
.
It is reported that the current process of domestic substitution of imports is being accelerated by the policy of preferential procurement of domestic equipment in various places
.
For example, Chutian Technology said in an earlier investigation by an agency that the company has been deploying import substitution in the high-end market for vaccine products many years ago
.
At present, the product performance and quality have been able to meet the needs of high-end customers; it has also entered the supply chain of the high-end vaccine industry and is competing with imported equipment
.
In general, in recent years, with the gradual maturity of domestic pharmaceutical equipment technology and the continuous increase of R&D investment, the current domestic pharmaceutical equipment market has a very complete range of products, and the products are of high quality and low price.
While meeting the needs of the domestic market, Overseas market demand is also growing
.
In this context, the domestic pharmaceutical equipment market is expected to develop in a higher-quality direction in the future, and it will prompt a continuous increase in the performance of a large number of companies
.
.
In this context, a large number of companies have ushered in the growth of performance, especially the leading companies
.
In order to maintain performance growth, pharmaceutical machine companies will continue to increase investment in research and development (Photo source: Pharmaceutical Network) At present, the listed companies in the domestic pharmaceutical equipment industry mainly include Xinhua Medical, Tofflon, Chutian Technology, Huasheng Co.
, Ltd.
, Tailin Biotechnology , Canaan Technology,
etc.
On the whole, the performance report cards of most listed pharmaceutical machine companies in 2021 are very dazzling.
Among them, the leading companies represented by Chutian and Tofflon have outstanding performance, and their net profit has increased significantly
.
For example, Chutian Technology disclosed in last year's third quarterly report that the company's main income was 3.
682 billion yuan, a year-on-year increase of 67.
24%; the net profit attributable to the parent was 401 million yuan, a year-on-year increase of 723.
53%
.
It also said that the main reason for the increase in revenue was a 98% increase in new orders compared to the same period in 2020
.
In addition, the third quarter report released by Xinhua Medical on October 28 also showed that the revenue in the first three quarters of 2021 was 7.
355 billion yuan, a year-on-year increase of 12.
60%, and the net profit was 438 million yuan, a year-on-year increase of 105.
59%
.
In addition, Tofflon expects that the net profit in the first three quarters of 2021 will also reach 519 million-562 million yuan, an increase of 80%-95% year-on-year; the net profit attributable to shareholders of listed companies is 558 million yuan, an increase of 93.
69% over the same period last year.
%
.
In addition to the continuous growth in performance, it is worth noting that the R&D investment of major enterprises is actually increasing continuously
.
Among them, Chutian Technology is very prominent in R&D investment.
Its R&D investment accounts for a high ratio of about 10% of revenue every year.
In the first three quarters of 2021, the company's R&D investment reached more than 300 million, a year-on-year increase of more than 60%
.
Since 2013, Tofflon's R&D investment has basically maintained at about 7% of its operating income, and its investment has continued to increase.
.
It is reported that in the first three quarters of this year, Tofflon's R&D expenses have exceeded the R&D expenses of 156 million yuan in 2020, an increase of 74.
81% over the same period of the previous year, reaching 166 million yuan
.
It can be seen from the above that R&D investment has become one of the core competitiveness of pharmaceutical machine companies to be invincible in the pharmaceutical equipment market
.
At the same time, innovation has also become an inexhaustible driving force for the development of pharmaceutical machine companies
.
Affected by this, the industry predicts that in the future, pharmaceutical machine companies will only continue to develop new technologies and products according to the needs of the industry and customers, innovate, improve and upgrade existing equipment, improve the level of China's pharmaceutical machine manufacturing industry, narrow the gap with imported equipment, and have More room for development
.
Of course, in the context of increasing innovation efforts, the industry believes that the import substitution of domestic pharmaceutical machines is also expected to accelerate
.
It is reported that the current process of domestic substitution of imports is being accelerated by the policy of preferential procurement of domestic equipment in various places
.
For example, Chutian Technology said in an earlier investigation by an agency that the company has been deploying import substitution in the high-end market for vaccine products many years ago
.
At present, the product performance and quality have been able to meet the needs of high-end customers; it has also entered the supply chain of the high-end vaccine industry and is competing with imported equipment
.
In general, in recent years, with the gradual maturity of domestic pharmaceutical equipment technology and the continuous increase of R&D investment, the current domestic pharmaceutical equipment market has a very complete range of products, and the products are of high quality and low price.
While meeting the needs of the domestic market, Overseas market demand is also growing
.
In this context, the domestic pharmaceutical equipment market is expected to develop in a higher-quality direction in the future, and it will prompt a continuous increase in the performance of a large number of companies
.
